Patents by Inventor Keethkumar Jain

Keethkumar Jain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD38 FUSION PROTEIN FORMULATION
    Publication number: 20250353923
    Abstract: Disclosed herein are compositions comprising a CD38-binding fusion protein, a buffer (e.g., a histidine/histidine-HCl buffer), a tonicity agent (e.g., arginine-HCl), a stabilizer (e.g., sucrose), and a surfactant (e.g., polysorbate such as polysorbate 80). In some aspects, the compositions described herein provide for stable storage of the CD38-binding fusion protein when lyophilized. Methods of treating cancer (e.g., CD38 positive cancer) using the composition described herein are also provided.
    Type: Application
    Filed: May 17, 2023
    Publication date: November 20, 2025
    Applicants: Takeda Pharmaceutical Company Limited, Cephalon LLC
    Inventors: Tomomi Sato, Nobel Truong, Keethkumar Jain, Nazila Salamat-Miller, Goutham Kodali, Shyam Mehta
  • STABLE FORMULATIONS FOR CNS DELIVERY OF ARYLSULFATASE A
    Publication number: 20200237883
    Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g., Metachromatic Leukodystrophy Disease). In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 5% of the ASA protein exists in aggregated form.
    Type: Application
    Filed: April 17, 2020
    Publication date: July 30, 2020
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias, Keethkumar Jain, Sujit Basu
  • Stable formulations for CNS delivery of arylsulfatase A
    Patent number: 10660944
    Abstract: The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease), In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: May 26, 2020
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias, Keethkumar Jain, Sujit Basu
  • STABLE FORMULATIONS FOR CNS DELIVERY OF ARYLSULFATASE A
    Publication number: 20190125841
    Abstract: The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease), In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form.
    Type: Application
    Filed: June 5, 2018
    Publication date: May 2, 2019
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias, Keethkumar Jain, Sujit Basu
  • STABLE FORMULATIONS FOR CNS DELIVERY OF ARYLSULFATASE A
    Publication number: 20140377244
    Abstract: The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease). In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 25, 2014
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias, Keethkumar Jain, Sujit Basu